Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials
March 28 2022 - 7:30AM
Nevakar Injectables Inc., a biopharmaceutical company developing
multiple sterile injectable products for use in the critical and
ambulatory care settings, announced today the launch of its
ready-to-use Ephedrine Sulfate Injection (“Ephedrine”), a
formulation pre-diluted to a 5mg/mL concentration and supplied in a
10mL vial. The product will be marketed and sold in the U.S. by the
Par Sterile Products (“Par”) business of Endo International plc
(“Endo”) (NASDAQ: ENDP). Ephedrine is a widely used injectable
vasopressor agent indicated for the treatment of clinically
important hypotension occurring during surgery.
“Ephedrine serves a very important role and is used by
anesthesiologists, nurse anesthetists, and other health care
professionals to treat hypotension during surgery,” stated Sriram
Ramanathan, MS, MBA, Chief Executive Officer of Nevakar
Injectables. “Our convenient and ready-to-use Ephedrine vial fills
a critical need in the marketplace by reducing the potential for
dilution errors and simplifying the drug preparation process.
Working together with our partners at Par, we are looking forward
to additional regulatory filings, FDA approvals, and commercial
launches associated with the products that Endo licensed from
Nevakar in 2018,” commented Mr. Ramanathan.
“We’re pleased to mark a milestone in our partnership with
Nevakar with this launch—a first step in fulfilling our joint
promise to serve our hospital customers and their patients through
a portfolio of enhanced injectable products,” said Scott Sims,
Senior Vice President and General Manager, Sterile Products at
Endo.
About Nevakar Injectables, Inc.Nevakar
Injectables, Inc. is a wholly owned subsidiary of Nevakar, Inc., a
fully integrated privately held, late-stage biopharmaceutical
company with an extensive portfolio of products in the ophthalmic
and injectable areas. Nevakar Injectables is developing a broad
portfolio of injectable products for use in the hospital and
ambulatory care settings. The Company has active programs in
critical patient care, acute pain management, long acting
injectables, and hospital injectables. For additional information
please visit www.nevakarinjectables.com.
About EndoEndo (NASDAQ: ENDP) is a specialty
pharmaceutical company committed to helping everyone we serve live
their best life through the delivery of quality, life-enhancing
therapies. Our decades of proven success come from passionate team
members around the globe collaborating to bring the best treatments
forward. Together, we boldly transform insights into treatments
benefiting those who need them, when they need them. Learn more
at www.endo.com or connect with us on LinkedIn.
About Par PharmaceuticalPar Pharmaceutical
develops, manufactures and markets safe, innovative and
cost-effective generic pharmaceutical and branded injectable
products that help improve patient quality of life. Par, among the
top leaders in the U.S. generics industry, possesses an
expanding portfolio that includes sterile injectables, alternative
dosage forms and other differentiated products. Par Pharmaceutical
is an Endo company. Learn more at www.parpharm.com.
Investor Contacts for Nevakar:
Marshall WoodworthChief Financial Officer(908) 367-7413E:
mwoodworth@nevakar.com
Lisa M. WilsonIn-Site Communications, Inc. T: (212) 452-2793E:
lwilson@insitecony.com
Endo (NASDAQ:ENDP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endo (NASDAQ:ENDP)
Historical Stock Chart
From Apr 2023 to Apr 2024